- Home
- BRTX vs MTVA Comparison
BRTX vs MTVA Comparison
Compare BRTX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- MTVA
- Stock Information
- Founded
- BRTX 1997
- MTVA 2014
- Country
- BRTX United States
- MTVA United States
- Employees
- BRTX N/A
- MTVA N/A
- Industry
- BRTX Managed Health Care
- MTVA
- Sector
- BRTX Health Care
- MTVA
- Exchange
- BRTX Nasdaq
- MTVA NYSE
- Market Cap
- BRTX 12.6M
- MTVA 14.3M
- IPO Year
- BRTX N/A
- MTVA N/A
- Fundamental
- Price
- BRTX $1.67
- MTVA $0.64
- Analyst Decision
- BRTX Strong Buy
- MTVA Strong Buy
- Analyst Count
- BRTX 1
- MTVA 2
- Target Price
- BRTX $18.00
- MTVA $7.50
- AVG Volume (30 Days)
- BRTX 256.1K
- MTVA 142.2K
- Earning Date
- BRTX 08-12-2025
- MTVA 08-13-2025
- Dividend Yield
- BRTX N/A
- MTVA N/A
- EPS Growth
- BRTX N/A
- MTVA N/A
- EPS
- BRTX N/A
- MTVA N/A
- Revenue
- BRTX $391,000.00
- MTVA N/A
- Revenue This Year
- BRTX $391.52
- MTVA N/A
- Revenue Next Year
- BRTX $3.50
- MTVA N/A
- P/E Ratio
- BRTX N/A
- MTVA N/A
- Revenue Growth
- BRTX 161.54
- MTVA N/A
- 52 Week Low
- BRTX $1.21
- MTVA $0.63
- 52 Week High
- BRTX $2.55
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- BRTX 46.78
- MTVA N/A
- Support Level
- BRTX $1.57
- MTVA N/A
- Resistance Level
- BRTX $1.72
- MTVA N/A
- Average True Range (ATR)
- BRTX 0.13
- MTVA 0.00
- MACD
- BRTX -0.01
- MTVA 0.00
- Stochastic Oscillator
- BRTX 20.65
- MTVA 0.00
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.